Clinical trials (indication, phase)	Date (year)
Protocol nb: **E7080-G000-604 EISAI** An open-label, multi-center, roll-over study to assess long term safety of Lenvatinib monotherapy or Lenvatinib combination regimen or comparator treatment arm to cancer patients in Eisai sponsored Lenvatinib trials	**2016 – 2022** **2 patients**
STUDY No. TST-EFS-04-MPP/16 Mattern Efficacy and safety of two- or three-times daily intranasal administration of testosterone gel (Tescum) in adult hypogonadal male patients, divided in 2 cohorts (cohort 1 – efficacy and long term safety assessment, cohort 2 – long term safety assessment)	**2017- 2020** **40 patients randomized**
Protocol nb: XL184–401 **EXELIXIS** A Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Cabozantinib (XL184) at 60 mg/Day Compared to 140 mg/Day in Progressive, Metastatic Medullary Thyroid Cancer Patients	**2018 –** **13 patients randomized**
Protocol Nb: COR-2017-01 Cortendo AB A Double-blind, Placebo-Controlled, Randomized Withdrawal Following Open-label Therapy Study to Assess the Safety and Efficacy of Levoketoconazole (2S, 4R ketoconazole) in the Treatment of Endogenous Cushing's Syndrome	**2018- 2021** **4 patients randomized**
Protocol 112025-002 HRA Pharma Prospective, single arm, open-label, multicenter, international study to assess the effects of metyrapone in patients with endogenous Cushing's syndrome during a 12-week treatment period followed by an extension period of 24 weeks	**2019- 2022** **1 patient**
Protocol nb: XL184–311 EXELIXIS A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Cabozantinib (XL184) in Subjects with Radioiodine-Refractory Differentiated Thyroid Cancer Who Have Progressed after Prior VEGFR-Targeted Therapy	**2020- 2022** **2 patients**
Trial ID: EX9536-4388 **Novo Nordisk** Semaglutide effects on cardiovascular outcomes in people with overweight or obesity (SELECT)	**2020- 2022** **3 patients**
CORT125134-455 CORCEPT Glucocorticoid Receptor Antagonism in the Treatment of Cushing Syndrome (GRACE): A Phase 3, Double-Blind, Placebo-Controlled, Randomized Withdrawal Study of the Efficacy and Safety of Relacorilant.	**2021- 2023** **8 patients**
CORT125134-456 CORCEPT Glucocorticoid Receptor Antagonism in the Treatment of Hypercortisolism in Patients with Cortisol-Secreting Adrenal Adenomas or Hyperplasia (GRADIENT): A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Relacorilant	**2021-** **7 patients, recruiting**
CORT125134-452 CORCEPT "An Open-Label Extension Study of the Safety of Relacorilant (CORT125134) in the Treatment of the Signs and Symptoms of Endogenous Cushing Syndrome."	**2021-** **8 patients, recruiting**
SPR001- 203 MEDPACE "A Randomized, Double-Blind, Placebo Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of SPROO 1 (Tildacerfont) in Adult Subjects with Classic Congenital Adrenal Hyperplasia"	**2023-** **1 patient**
SPR001- 204 MEDPACE "A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of SPR001 (Tildacerfont) in Reducing Supraphysiologic Glucocorticoid Use in Adult Subjects with Classic Congenital Adrenal Hyperplasia'""	**2023-** **3 patients**
SPI-62-CL-2001 Sparrow Pharmaceuticals, Inc "SPI-62 as a treatment for Adrenocorticotropic Hormone dependent Cushing's Syndrome"	**2023-** **1 patient, recruiting**
SPI-62-CL-2002 Sparrow Pharmaceuticals, Inc "SPI-62 as a treatment for hypercortisolism related to a benign adrenal tumor"	**2023-** **recruiting**